Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took the first dose of Vivotif with food and other doses were taken on an empty stomach; Case reference number US-BN-2025-001530 is a spontaneous case initially received from a pharmacist via Communication (reference number: USBAV25-2269) on 10-Sep-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif with food (batch number: unknown), at unknown dose, orally for indication of typhoid fever prophylaxis (explicitly coded as: 'product administration error'). On an unspecified date, an unknown amount of time after the first dose, reported as on alternate days, the patient took the second dose of Vivotif on empty stomach (batch number: unknown), at unknown dose, orally. On an unspecified date, an unknown amount of time after the second dose, reported as on alternate days, the patient took the third dose of Vivotif on empty stomach (batch number: unknown), at unknown dose, orally. On an unspecified date, an unknown amount of time after the third dose, reported as on alternate days, the patient took fourth dose of Vivotif with empty stomach (batch number: unknown), at unknown dose, orally at unknown site of administration. At the time of the initial report, it was unknown if the patient experienced adverse event due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age took the first dose of Vivotif with food, for indication of typhoid fever prophylaxis, which is considered as product administration error. It was unknown if the patient experienced adverse event due to Vivotif. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took the first dose of Vivotif with food, for indication of typhoid fever prophylaxis, which is considered as product administration error. It was unknown if the patient experienced adverse event due to Vivotif. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.